Dr. Simon Moroney Awarded Bavarian State Medal for Outstanding
Services to the Bavarian Economy
2009-11-24 11:20:09 -
London, November , 24, 2009
Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced
today that its co-founder and CEO Dr. Simon Moroney was awarded the
Bavarian State Medal for Outstanding Services to the Bavarian
Economy. The award ceremony took place at the Bavarian State Ministry
of Economy, Infrastructure, Transport and Technology in Munich,
Germany, on November 23, 2009.
"I am pleased to award Dr. Moroney the Bavarian State Medal for
Outstanding Services for his contribution to the Bavarian
biotechnology sector and the Bavarian economy in general", commented
Martin Zeil, Bavarian State Ministry of Economy, Infrastructure,
Transport and Technology. "MorphoSys is a success story in the German
biotech landscape and acts as a key factor for Munich's endeavors to
become a leading biotechnology region. Thanks to the sustainable
business model Dr. Moroney is pursuing with MorphoSys, the company
was able to provide new jobs even in these challenging markets."
Since being founded in 1992, MorphoSys has been one of the most
closely followed German biotechnology companies. From its start as a
core team of young researchers, it has grown into a globally
operating organization with some 400 employees. Within the
biotechnology sector, MorphoSys is viewed as a technology leader and
the partner of choice for antibody development.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel
antibodies for therapeutic, diagnostic and research applications. The
Company's HuCAL technology is one of the most powerful methods
available for generating fully human antibodies. By successfully
applying this and other proprietary technologies, MorphoSys has
become a leader in the field of therapeutic antibodies, one of the
fastest-growing drug classes in human health-care. Through its
alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The
Company is expanding its drug pipeline by adding new partnered
programs, and by building a portfolio of fully-owned therapeutic
antibodies. For its proprietary portfolio, the Company is focused on
the areas of oncology and inflammation, within which it plans to have
eight active programs by the end of 2009. Its most advanced program
is MOR103, a first-in-class, fully human antibody against GM-CSF.
MorphoSys expects to commence a Phase Ib/IIa trial of this antibody
in rheumatoid arthritis patients in the second half of 2009. Via its
business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock
Exchange under the symbol "MOR". For further information, visit
www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered
trademarks of MorphoSys AG
This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far
as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Phone: +49 (0) 89 / 899 27-122
claudia.gutjahr-loeser@morphosys.com
Mario Brkulj
Senior Manager Corporate Communications & IR
Phone: +49 (0) 89 / 899 27-454
mario.brkulj@morphosys.com
Jessica Kulpi
Specialist Corporate Communications & IR
Phone: +49 (0) 89 899 27 332
jessica.kulpi@morphosys.com
hugin.info/130295/R/1356844/329880.pdf
hugin.info/130295/R/1356844/329897.jpg
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN:
663200; ISIN: DE0006632003; Index: CDAX, HDAX, Prime All Share, TECH
All Share, TecDAX, MIDCAP;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Stuttgart, Regulierter Markt in Frankfurter
Wertpapierbörse;
